Skip to main content
. Author manuscript; available in PMC: 2023 Oct 1.
Published in final edited form as: Adv Ther (Weinh). 2022 Aug 4;5(10):2200130. doi: 10.1002/adtp.202200130

Fig 7. In-silico modeling and comparison of 4-1BB and CD28 CAR T-cell products.

Fig 7.

(A) Peak probability of severe CRS and the day of the peak, for a virtual cohort of 200 virtual patients, with CAR T-cell response two, five, and ten times slower. Cohort size = 200. (B) Time series of tumor burden and probability of severe CRS of patients #1 and #2, with control or five times slower CAR T-cell response. (C) In a virtual cohort of 200 patients, the peak probability of severe CRS and the tumor burden at day 60 with control or five times slower CAR T-cell response. Lines link individual virtual patients. Cohort size = 200.